Reuters reports the U.S. Securities and Exchange Commission's top enforcement chief said many pharmaceutical companies are failing to accurately portray their dealings with federal drug regulators.
Andrew Ceresney, the SEC's enforcement director, said the agency has seen a lot of problems with disclosures by pharmaceutical companies, including on 8-Ks - a form companies file when they need to disclose an event that is "material" to their business, the article said.
Ceresney said the SEC has taken a number of enforcement actions in recent years against companies for problematic disclosures tied to FDA approvals. Read the Reuters story
